share_log

BetterLife Pharma Inc. (OTCMKTS:BETRF) Sees Large Decrease in Short Interest

Defense World ·  Oct 3, 2022 16:42

BetterLife Pharma Inc. (OTCMKTS:BETRF – Get Rating) was the target of a significant drop in short interest during the month of September. As of September 15th, there was short interest totalling 51,500 shares, a drop of 5.5% from the August 31st total of 54,500 shares. Based on an average trading volume of 64,500 shares, the short-interest ratio is currently 0.8 days.

BetterLife Pharma Stock Performance

BETRF opened at $0.14 on Monday. The company's 50 day simple moving average is $0.14 and its 200 day simple moving average is $0.11. BetterLife Pharma has a 1 year low of $0.05 and a 1 year high of $0.30. The stock has a market capitalization of $7.31 million, a PE ratio of -1.58 and a beta of 2.72.

Get BetterLife Pharma alerts:

BetterLife Pharma Company Profile

(Get Rating)

BetterLife Pharma Inc, a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections.

Featured Articles

  • Get a free copy of the StockNews.com research report on BetterLife Pharma (BETRF)
  • Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
  • Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
  • Magna International is Your Auto and EV One-Stop Shop Stock
  • EV Battery Maker Freyr Set For Major Global Expansion
  • MarketBeat: Week in Review 9/26 – 9/30

Receive News & Ratings for BetterLife Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BetterLife Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment